Herantis Pharma Says Clinical Evidence Supports HER-096 Phase 2 Study Design
The Phase 2 study will assess HER-096’s efficacy in approximately 100 participants. The body text is truncated after “smartphone-b.”
The Phase 2 study will assess HER-096’s efficacy in approximately 100 participants. The body text is truncated after “smartphone-b.”